Previous 10 | Next 10 |
- Preclinical data on AUTO5 in T cell lymphoma and solid tumor data on AUTO6NG in small cell lung cancer and AUTO7 in prostate cancer - Conference Call and Webcast to be held Thursday, June 25, 2020 at 8:30 am EDT / 1:30 pm BST LONDON, May 15, 2020 (GLOBE NEWSWIRE) -- Autolus ...
– Data builds on positive data presented at American Society of Hematology in December 2019 and EHA-EMBT 2 nd European CAR T Cell Meeting in February 2020 – Conference Call and Webcast to be held Monday, June 15, 2020 at 8:30 am EDT / 1:30 pm BST LONDON, Ma...
- Virtual oral presentation will include additional patient data as well as longer term data on previously treated patients - Conference Call and Webcast to Be Held Monday, June 1, 2020 at 8:30 am EDT / 1:30 pm BST LONDON, May 14, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics ...
Investment thesis: As mentioned in our previous articles, Eonia Research focuses heavily on analyzing the underlying science of biotechs. After a prolonged search, we have found an intriguing biotech operating in the chimeric antigen receptor T-cell (CAR-T) space, Autolus therapeutics ( AUTL...
Autolus Therapeutics Plc (AUTL) Q1 2020 Earnings Conference Call May 7, 2020 08:30 ET Company Participants Lucinda Crabtree - Vice President, Investor Relations Christian Itin - Chairman & Chief Executive Officer Andrew Oakley - Senior Vice President & Chief Financial Off...
Image source: The Motley Fool. Autolus Therapeutics Plc (NASDAQ: AUTL) Q1 2020 Earnings Call May 07, 2020 , 8:30 a.m. ET Operator Continue reading
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
The following slide deck was published by Autolus Therapeutics plc in conjunction with their 2020 Q1 earnings Read more ...
Autolus Therapeutics (NASDAQ: AUTL ): Q1 GAAP EPS of -$0.60 beats by $0.14 . More news on: Autolus Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more ...
- Conference Call to be held on May 7, 2020 at 8:30 am EDT/1:30 pm BST- LONDON, May 07, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its financial a...
News, Short Squeeze, Breakout and More Instantly...
Autolus Therapeutics plc Company Name:
AUTL Stock Symbol:
NASDAQ Market:
Autolus Therapeutics plc Website:
LONDON, July 26, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2024 financial results and operational highlights befo...
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention Ongoing CAR T persistence was associated wi...